EGF and gastric carcinoma: To verify if the observed behaviour was peculiar to GTL16 cells or if it was shared by other gastric cancer cells, bearing MET overexpression due to gene amplification (MKN45, SNU5, Hs746T gastric carcinoma cell lines), we treated them with PHA, in the absence or in the presence of either EGF or HRG1-β1.